Ferrous bisglycinate, a dietary supplement form of iron bound to the amino acid glycine, is used to refill low iron stores and correct anemia. In deficiency, it reliably does both, with less nausea and constipation than standard iron forms. In people with enough iron, the body cannot remove surplus, and genetic studies tie higher lifelong iron to a shorter life. Evidence supports it for confirmed deficiency, not general longevity use. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Ferritin | Above 30 μg/L (75 ng/mL or less: restless legs treatment threshold) | Tracks repletion; safety check for overshoot |
| Transferrin saturation | 20–45%; overload above 45% (premenopausal women) or 50% (men, postmenopausal women) | Safety check: rising saturation stops or reduces use |
| Hemoglobin | 12.0–15.5 g/dL (women), 13.5–17.5 g/dL (men) | Rises when anemia is corrected |
| Mean corpuscular volume | 80–100 fL | Small cells normalize with repletion |
| Serum iron | Not specified in the ER | Baseline iron status |
| C-reactive protein | Not specified in the ER | Interprets ferritin |
| HFE genotype | Not specified in the ER | Identifies hereditary hemochromatosis risk |
Cadence: Baseline before starting; hemoglobin at 2–4 weeks; ferritin, transferrin saturation and hemoglobin at 8–12 weeks, then every 3–6 months while supplementation continues; morning samples, at least 24 hours without iron